123I-MIBG myocardial scintigraphy for the diagnosis of DLB: a multicentre 3-year follow-up study

Background and purpose We previously reported the usefulness of iodine-123 metaiodobenzylguanidine ( 123 I-MIBG) myocardial scintigraphy for differentiation of dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD) in a cross-sectional multicentre study. The aim of this study was, by using reassessed diagnosis after 3-year follow-up, to evaluate the diagnostic accuracy of 123 I-MIBG scintigraphy in differentiation of probable DLB from probable AD. Methods We undertook 3-year follow-up of 133 patients with probable or possible DLB or probable AD who had undergone 123 I-MIBG myocardial scintigraphy at baseline. An independent consensus panel made final diagnosis at 3-year follow-up. Based on the final diagnosis, we re-evaluated the diagnostic accuracy of 123 I-MIBG scintigraphy performed at baseline. Results Sixty-five patients completed 3-year follow-up assessment. The final diagnoses were probable DLB (n=30), possible DLB (n=3) and probably AD (n=31), and depression (n=1). With a receiver operating characteristic curve analysis of heart-to-mediastinum (H/M) ratios for differentiating probable DLB from probable AD, the sensitivity/specificity were 0.77/0.94 for early images using 2.51 as the threshold of early H/M ratio, and 0.77/0.97 for delayed images using 2.20 as the threshold of delayed H/M ratio. Five of six patients who were diagnosed with possible DLB at baseline and with probable DLB at follow-up had low H/M ratio at baseline. Conclusions Our follow-up study confirmed high correlation between abnormal cardiac sympathetic activity evaluated with 123 I-MIBG myocardial scintigraphy at baseline and the clinical diagnosis of probable DLB at 3-year follow-up. Its diagnostic usefulness in early stage of DLB was suggested. Trial registration number UMIN00003419.